Rockefeller Capital Management L.P. Increases Stock Position in GRAIL, Inc. $GRAL

Rockefeller Capital Management L.P. raised its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 18.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,577 shares of the company’s stock after acquiring an additional 10,565 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.17% of GRAIL worth $5,870,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. N.E.W. Advisory Services LLC acquired a new position in shares of GRAIL in the 4th quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in GRAIL in the 4th quarter valued at approximately $28,000. Elyxium Wealth LLC purchased a new stake in GRAIL in the fourth quarter valued at approximately $31,000. Comerica Bank raised its position in GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Finally, Intesa Sanpaolo S.p.A. acquired a new position in GRAIL during the fourth quarter worth $44,000.

Insider Buying and Selling

In related news, CFO Aaron Freidin sold 45,806 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer directly owned 260,669 shares in the company, valued at approximately $13,012,596.48. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 232,464 shares of company stock worth $11,621,242. 1.83% of the stock is owned by corporate insiders.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL completed a $110 million equity financing with Samsung affiliates, adding capital that could support operations and reduce near-term financing pressure. GRAIL Completes $110 Million Equity Financing With Samsung Entities
• Neutral Sentiment: Multiple law firms issued notices and deadline reminders about an already-filed securities class action, including a lead-plaintiff deadline of August 4, 2026. ROSEN, LEADING TRIAL LAWYERS, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL
• Neutral Sentiment: Short-interest data was reported with no meaningful shares outstanding, offering little new signal for trading direction.
• Negative Sentiment: Several firms announced or promoted class-action litigation alleging investors were harmed by GRAIL’s disclosures around the NHS-Galleri trial failure, reinforcing legal overhang and potential damages risk. GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout — HBSS

GRAIL Trading Down 1.0%

GRAIL stock opened at $65.92 on Friday. The firm has a market capitalization of $2.83 billion, a P/E ratio of -6.36 and a beta of 3.15. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84. The stock’s fifty day simple moving average is $60.67 and its 200-day simple moving average is $71.58.

GRAIL (NASDAQ:GRAL) last released its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The firm had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. Sell-side analysts predict that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on GRAL. TD Cowen raised their price target on GRAIL from $65.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wolfe Research assumed coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Guggenheim decreased their target price on GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Robert W. Baird set a $70.00 target price on GRAIL in a report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GRAIL presently has a consensus rating of “Hold” and a consensus target price of $67.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.